OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.680
+0.020 (1.20%)
At close: Apr 2, 2026, 4:00 PM EDT
1.660
-0.020 (-1.19%)
After-hours: Apr 2, 2026, 4:10 PM EDT
OKYO Pharma Employees
OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.
Employees
4
Change (1Y)
1
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$1,153,335
Market Cap
88.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 4 | 1 | 33.33% |
| Mar 31, 2024 | 3 | -5 | -62.50% |
| Mar 31, 2023 | 8 | 1 | 14.29% |
| Mar 31, 2022 | 7 | 1 | 16.67% |
| Mar 31, 2021 | 6 | 2 | 50.00% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortress Biotech | 101 |
| PolyPid | 73 |
| Seres Therapeutics | 66 |
| Aardvark Therapeutics | 40 |
| Vivani Medical | 37 |
| Gain Therapeutics | 25 |
| NeurAxis | 21 |
| Filana Therapeutics | 20 |
OKYO News
- 14 days ago - OKYO Pharma Announces Chairman and Founder Acquires Shares - GlobeNewsWire
- 14 days ago - OKYO Pharma Announces Director Acquires Shares - GlobeNewsWire
- 14 days ago - OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - GlobeNewsWire
- 15 days ago - OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - GlobeNewsWire
- 5 weeks ago - OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - GlobeNewsWire
- 7 weeks ago - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares - GlobeNewsWire
- 7 weeks ago - OKYO Pharma Announces Public Offering of Ordinary Shares - GlobeNewsWire
- 7 weeks ago - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners - GlobeNewsWire